arrow
F

Fabio Ciceri

ospedale san raffaele
H指数:116
被引数:5.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: a study from the ALWP/EBMT

更正:与含移植后环磷酰胺的错配无关供者异基因移植相比,T细胞充足型半相合移植在二次急性髓系白血病首次完全缓解患者中的研究:ALWP/EBMT研究

2026-11-050
OAAI
Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

纠正:基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较,用于接受异基因造血干细胞移植的AML患者,移植预处理强度为中等强度方案:代表EBMT急性白血病工作组进行的登记研究

2026-10-230
OAAI
Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

出版商更正:定义造血移植和细胞治疗领域的全球优先事项:EBMT全球委员会的一份声明文件

2026-10-120
OAAI
GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party

老年患者移植排斥反应预防:移植后环磷酰胺还是抗胸腺细胞球蛋白?EBMT移植并发症工作组研究

2026-10-060
PRE
Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较:在异基因无关供者移植且采用中间强度预处理方案的患者中治疗AML的登记研究——代表EBMT急性白血病工作组

2026-09-100
OAAI
Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity

化疗诱导衰老通过降低EZH2活性促进急性髓系白血病的免疫原性

2026-09-040
OA
Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT

异基因干细胞移植联合移植后环磷酰胺治疗急性髓系白血病患者:单次诱导与两次诱导后达到首次完全缓解的对比研究——来自ALWP/EBMT的研究

2026-09-020
OAAI
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

更正:费城染色体阳性急性淋巴细胞白血病合并附加细胞遗传学异常的移植结局:欧洲血液与骨髓移植学会急性白血病工作组的研究

2026-08-310
OAAI
Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee

定义全球造血移植和细胞治疗的优先事项:EBMT全球委员会声明文件

2026-08-110
OAAI
Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo)

异基因移植后急性髓系白血病复发的预防策略:GITMO(意大利骨髓移植组)全国调查

2026-08-050
PRE
Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
2026-07-200
PRE
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

欧洲血液与骨髓移植学会急性白血病工作组关于调节方案对<40岁处于完全缓解期并接受HCT治疗的AML患者结局的影响(移植调节强度评分为3.5-4.0)的研究

2026-07-170
PRE
Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities

携带附加细胞遗传学异常的费城染色体阳性急性淋巴细胞白血病的移植结果

2026-07-130
OAAI
Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT

氟达拉滨联合曲奥舒凡或全身照射作为异基因造血干细胞移植前急性淋巴细胞白血病的预处理疗法。来自EBMT ALWP的回顾性配对分析

2026-07-080
OA
A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia

异基因移植后急性白血病患者无白血病生存的综合性预后模型

2026-07-020
OA
T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

T细胞富集的半相合移植与使用移植后环磷酰胺的错配无关供者异基因移植治疗首次完全缓解期继发性急性髓系白血病患者的比较:一项来自ALWP/EBMT的研究

2026-06-270
OAAI
Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT

非清髓性预处理与减低强度预处理在≥65岁急性髓系白血病患者异基因造血干细胞移植中的比较:EBMT ALWP的研究

2026-06-210
PRE
Claudio Bordignon

Claudio Bordignon

2026-06-160
PRE